BioSpace News Archive

Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO’s conference call regarding the presentation of the interim report January-March 2022.

GlaxoSmithKline plc and Sierra Oncology, Inc announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion.

Highlight Therapeutics, a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announced positive results of a Phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma whose disease had progressed on first-line anti-PD1-based therapy.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted Novavax conditional marketing authorization for Nuvaxovid™ COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Zomedica Corp. is pleased to announce that the PulseVet system has been named the Official Shock Wave Therapy of the American Quarter Horse Association.

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen program, following a comprehensive post-hoc analysis of the data from the Phase 2/3 Illuminate trial in people with CEP290-mediated Leber congenital amaurosis 10, or LCA10, a severe inherited retinal disease.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the company will participate in investor meetings at the Kempen Life Sciences Conference being held in Amsterdam, April 20 - 21, 2022.

Axogen, Inc. today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022 after the market closes.

Imcyse today announced the first patient has been dosed in the adaptive Phase 1/2 clinical trial evaluating ImotopeTM IMCY-0141 in patients with relapsing-remitting multiple sclerosis (RRMS).

Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 4, 2022 , at 8:00 a.m. CDT to review third quarter fiscal 2022 financial results.